ECE2024 Poster Presentations Endocrine-Related Cancer (40 abstracts)
Possible prognostic role of BMI before chemotherapy in the outcomes of women with ovarian cancer
Stavroula Paschou 1 , Aggeliki Andrikopoulou 2 , Nikoletta Mili 3 , Anna Svarna 2 , Maria Kaparelou 2 , Katerina Stefanaki 1 , Nikolaos Dedes 2 , Efstathia Liatsou 2 , Nikolaos Thomakos 4 , Dimitrios Haidopoulos 4 , Theodora Psaltopoulou 2 , Efstathios Kastritis 2 , Flora Zagouri 2 , Meletios-Athanasios Dimopoulos 2 & Michalis Liontos 2
1Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Athens, Greece; 2Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Hematology and Oncology Unit, Department of Clinical Therapeutics, Athens, Greece; 3Aretaieio Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., 2nd Department of Obstetrics and Gynaecology,, Athens, Greece; 4Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., 1st Department of Obstetrics and Gynaecology, Athens, Greece
Introduction: Survival rates for ovarian cancer remain distressingly low. Despite established prognostic factors, the need for identifying modifiable parameters to influence survival outcomes is imperative. Overweight and obesity, prevalent conditions, have been implicated in cancer development and potentially poor survival. However, conflicting data on the association of Body Mass Index (BMI) with Progression-Free Survival (PFS) and Overall Survival (OS) in ovarian cancer patients necessitate further exploration.
Aim: This study aims to investigate the prognostic role of BMI before chemotherapy in women with ovarian cancer, specifically focusing on PFS and OS.
Patients and methods: A retrospective analysis encompassed 1136 patients diagnosed with ovarian carcinomas between 1995 and 2018. Patients were categorized based on BMI at presentation, and a comprehensive examination of clinicopathological, treatment, and survival data was conducted.
Results: In the patient population, normal weight patients (BMI<25 kg/m2) demonstrated a median PFS of 12.8 months (95% CI 11.7–13.9 months), while overweight/obese patients (BMI≥25 kg/m2) exhibited a significantly longer median PFS of 14.9 months (95% CI 13.6–16.4 months, P=0.006). No statistically significant difference was noted in median OS between the two BMI groups. Subgroup analysis for different histological subtypes revealed a statistically significant benefit for overweight and obese patients with serous and endometrioid histology (mPFS 12.9 months, 95% CI 11.7–14.0 vs 15.6 months, 95% CI 13.9–17.3, P=0.012 and 14.6 months 95% CI 13.7–15.5 vs 25.6 months, 95% CI 9.5–41.7, P=0.031, respectively). Additionally, BMI≥25 kg/m2 demonstrated a significant advantage in advanced-stage disease.
Conclusions: The study underscores the intricate association between BMI and ovarian cancer prognosis. While PFS demonstrated a significant difference between BMI groups, OS did not exhibit such disparity.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more